ArticleScientific reports2026
MetaXVP: an interpretable machine learning framework for deep insight into variant pathogenicity and VUS classification.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The interpretation and classification of nonsynonymous single nucleotide variants (nsSNVs) remains a significant challenge in clinical genomics particularly for variants of uncertain significance (VUS). Although many computational methods have been developed for predicting variant pathogenicity, their performance remains limited and often lacks interpretability. To address these limitations, we developed MetaXVP (Meta eXplainable XGBoost Variant Predictor) ,designed to combine high predictive performance with effective feature explanation using rigorous methodology. MetaXVP was built using the XGBoost algorithm and trained on high-confidence pathogenic and benign nsSNVs from ClinVar (submissions up to April 2024). Feature annotations were obtained from dbNSFP v4.7 (last updated March 2024) where 32 features spanning conservation metrics, functional scores, ensemble predictors, and allele frequencies were selected through correlation-based feature selection. SHapley Additive exPlanations (SHAP) and Local Interpretable Model-agnostic Explanations (LIME) methods were also used to make the model interpretable. Final evaluation was conducted on four independent ClinVar test sets (isolated from training data), a TP53 functional dataset, and a cancer somatic driver dataset using area under the receiver operating characteristic curve (AUROC), area under the precision-recall curve (AUPRC) and evaluation metrics based on Bayesian threshold calculations. In addition, the performance was compared with 32 individual features and 6 benchmark tools. MetaXVP achieved high classification performance across ClinVar test sets (AUROC = 0.991 for pathogenic/benign and 0.986 for VUS reclassified to pathogenic/benign), and somatic cancer test set (AUROC = 0.924). In addition, the stability of the Bayesian decision threshold was evaluated using bootstrap resampling, demonstrating robustness to sampling variability. SHAP analysis also revealed that ensemble predictors such as ClinPred and gMVP; and population allele frequency (gnomAD) were among the most influential features in the model based on mean absolute SHAP values. Pre-computed MetaXVP scores for all potential human nsSNVs (~ 83 million) are provided at https://github.com/Masouddehghant/MetaXVP for community use, which is particularly helpful for classification of VUS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.